30th May 2025 10:08
(Alliance News) - Danaher Corp on Thursday said it has entered a partnership with AstraZeneca PLC to develop and commercialise tools and tests for precision medicine treatments, including artificial intelligence algorithms.
The Washington DC-based life sciences and diagnostics company said the aim of the partnership with Cambridge, England-based pharmaceutical firm AstraZeneca is to scale precision medicine, including developing AI-powered diagnostics.
"Precision medicines are more targeted than standard therapies and thus require precision diagnostics to determine which patients are most likely to benefit," said Danaher Executive Vice President Julie Sawyer Montgomery.
"We are excited to work with AstraZeneca on the goal of creating novel tests to increase access to precision medicines, helping ensure that no patients are left behind."
The firm said the partnership means the new Danaher Centers for Enabling Precision Medicine will be able to support "a more streamlined, end-to-end development process".
The initial focus of the partnership will be on digital and computational pathology products and AI-assisted algorithms, Danaher said.
"Our partnership with Danaher and [Danaher subsidiary] Leica Biosystems underscores our commitment to pioneering AI-based diagnostics which can improve patient selection, and our belief that collaboration is a critical accelerant for such progress," said AstraZeneca Executive Vice President Susan Galbraith.
Shares in Danaher closed up 0.8% at USD190.47 in New York on Thursday. AstraZeneca shares were 0.8% higher at 10,476.00 pence in London on Friday morning.
By Michael Hennessey, Alliance News reporter
Comments and questions to [email protected]
Copyright 2025 Alliance News Ltd. All Rights Reserved.
Related Shares:
Astrazeneca